Cheng Yi Pharmaceutical insists on annual dividends to benefit all investors

After the promulgation of the new National Ninth Article, it has caused a warm response in the capital market. In recent days, investors have been paying close attention to the sustainable development, performance support, and dividend returns of listed companies. The reporter learned from Cheng Yi Pharmaceutical that since its listing on the main board of the Shanghai Stock Exchange in March 2017, the company has adhered to annual dividends, and the average ratio of the dividend amount to the net profit of the year is over 34%, benefiting all investors.

On March 12th, a group of chief pharmaceutical researchers from securities companies came to the company for research.

The reporter learned that in the three years before going public, the annual dividend was between 35 million yuan and 47 million yuan; After going public for three years, the annual dividend is close to 60 million yuan. The company has also conducted four rounds of capital reserve conversion to increase its share capital, each time receiving a 10 out of 4 bonus. The company's share capital has also increased from 85.2 million yuan to 327.30432 million yuan, reflecting a synchronous increase in the return to investors after performance thickening. Meanwhile, in the past three years, the cumulative amount of R&D investment has been 116 million yuan, with R&D investment accounting for 5.5% of operating revenue. Innovation driven has become the driving force for increasing performance.

Since the beginning of the year, the company has accelerated the development strategy of "two strong and one large", seized the opportunity of the national development of "silver economy" and the big health industry, built a "big health product matrix", and made significant progress in various industries by expanding and strengthening marine biopharmaceuticals. The parent company has successfully passed the national high-tech enterprise re certification, and the subsidiary Fujian Huakang Pharmaceutical Co., Ltd. has passed this certification for the first time; The company's flagship product, Glucosamine Hydrochloride Capsules, has entered the "Henan Leading 13 Province Alliance Procurement", with 20 winning provinces in the procurement, contributing to the thickening of performance; Lidocaine hydrochloride injection has passed the national generic drug consistency evaluation; On the basis of obtaining the first health food production license in Wenzhou, the "Food Fish Oil and Additive Nitrogen Production License" has been approved; The company was also awarded the title of Excellent Unit in the Construction of "Safe Enterprises" in the Industrial Industry of Zhejiang Province for the years 2022-2023. Since the beginning of the year, the proportion of controlling shareholders acting in unison to increase their holdings of the company's shares has reached 1%. The company has received more than ten batches of institutional investors, including Debon Securities, Minsheng Securities, Xinda Securities, Everbright Securities, and Zishi Investment, from its Shanghai headquarters and Dongtou Manufacturing Department, to conduct research and inspection, and has received praise from investors.

①On April 18th, a group of old experts from Beijing and Shanghai inspected the company's ammonia sugar production line.

②At the end of last year, the company held a production and operation plan approval meeting for 2024 and deployed various tasks for this year.

Appendix: Cash Dividends and R&D Expenses Investment of Cheng Yi Pharmaceutical

Unit: 10000 yuan

(Source: April 19th, Volkswagen Securities News)